Anisha Doshi

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Jeremy Chataway, Floriana De Angelis, Peter Connick et al. · The Lancet Neurology · 2020 · 130 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Plasma melatonin is reduced in Huntington's disease

Eirini Kalliolia, Edina Silajdžić, Rajasree Nambron et al. · Movement Disorders · 2014 · 112 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

Peter Connick, Floriana De Angelis, Richard Parker et al. · BMJ Open · 2018 · 56 citations · Full text

Medicine, Neurology, Pharmacology +17

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial

Thomas Williams, Carmen Tur, Arman Eshaghi et al. · Multiple Sclerosis Journal · 2022 · 29 citations · Full text

Medicine, Neurology, Neuroscience +17

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT

Floriana De Angelis, Peter Connick, Richard Parker et al. · Efficacy and Mechanism Evaluation · 2020 · 27 citations · Full text

Medicine, Neurology, Pharmacology +15